Skip to main content
. 2022 Feb 14;9(6):ofac079. doi: 10.1093/ofid/ofac079

Table 5.

Nonserious Adverse Events With a Frequency Threshold >5% Among Patients Who Received Ceftolozane-Tazobactam and Those Who Received the Standard of Care

Event Ceftolozane/Tazobactam
(n = 47)
Standard of Care
(n = 50)
Total 9 (19) 6 (12)
ALT elevation (>ULN) 3 (6) 3 (6)
Urinary tract infection 3 (6) 0 (0)
Rash 5 (11) 3 (6)

Data are presented as No. (%) of patients. Events were collected by systematic assessment.

Abbreviation: ALT, alanine aminotransferase; ULN, upper limit of normal.